AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.
Condensed interim financial statements 30 June 2007
The attached consolidated income statement, balance sheet and cash flow statement are derived from our condensed interim financial statements 30 June 2007 which can be found on our website http://www.amtpharma.com
Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and
expectations for future operations, prospects and financial condition.
Words such as "strategy," "expects," "plans," "anticipates," "believes,"
"will," "continues," "estimates," "intends," "projects," "goals," "targets"
and other words of similar meaning are intended to identify such
forward-looking statements. Such statements are based on the current
expectations of the management of Amsterdam Molecular Therapeutics only.
Undue reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be affected by
factors that are beyond the control of AMT. Actual results could differ
materially from current expectations due to a number of factors and
uncertainties affecting AMT's business, including, but not limited to, the
timely commencement and success of AMT's clinical trials and research
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2007 PR Newswire.
All rights reserved